Oncolytics Logo
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

News Releases

  • News Releases
Latest News Release
Dec 13, 2001

Oncolytics Biotech Inc. Announces REOLYSIN® Phase I Clinical Trial Interim Results

Dec 12, 2001

Oncolytics Announces Webcast of REOLYSIN® Phase I Interim Results Conference Call

Dec 4, 2001

Oncolytics Biotech Inc. Announces REOLYSIN(R) Systemic Animal Toxicology Results

Nov 29, 2001

Oncolytics Biotech Inc. Completes Enrollment For REOLYSIN® Phase I Clinical Trial

Nov 7, 2001

ONCOLYTICS BIOTECH INC. ANNOUNCES THIRD QUARTER RESULTS

Oct 22, 2001

Oncolytics Biotech, Inc. to Present at Techvest, LLC Emerging Healthcare Forum

Oct 11, 2001

Oncolytics Biotech Inc. Announces Approval to Proceed with Clinical Trial to Evaluate REOLYSIN(R) for the Treatment of Prostate Cancer

Oct 5, 2001

Oncolytics Biotech Inc. Begins Trading on NASDAQ Small Cap Market Today

  • 1
  • 2
  • 3

Year
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • News
Dec 27, 2017

Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas Read More

Dec 5, 2017

Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer Read More

View all news articles
Aug 9, 2016

Exploring REOLYSIN®’s Objective Response Rate in Females with Colorectal Cancer Read More

Exploring REOLYSIN<sup>®</sup>’s Objective Response Rate in Females with Colorectal Cancer thumbail
View all blog posts

LATEST TWEETS

@Oncolytics May 16, 2022

Due to unexpected COVID-19 issues, Oncolytics will not be able to participate in the RBC Conference on Wednesday. W… https://t.co/qnLGkbf6Wp

@Oncolytics May 10, 2022

CEO Matt Coffey will be at the 2022 @RBC Capital Markets Global Healthcare Conference participating in a fireside c… https://t.co/8fVv0S6Gbk

Follow us on Twitter
  • About Us
    • Our Company
    • Leadership Team
  • REOLYSIN®
    • What is REOLYSIN®?
    • Clinical Trials
    • Intellectual Property
    • Papers & Presentations
  • Investor Center
    • Investor Overview
    • Stock Information
    • Financials
    • Presentations
    • Corporate Governance
    • RSS Feeds
    • Analyst Coverage
  • News
  • Contact

Sign up to receive email updates

Sign Up
Linkedin Icon
  • Privacy | Legal Notice
Copyright © Oncolytics Biotech® Inc. 2022 All rights reserved

Site by
Site by Pace Creative Alberta Site by Pace Creative Alberta